High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis.
作者信息
Messori Andrea, Peyvandi Flora, Trippoli Sabrina, Palla Roberta, Rosendaal Frits R, Mannucci Pier Mannuccio
机构信息
HTA Unit, ESTAR, Regional Health Service, Florence, Italy.
"A. Bianchi Bonomi" Haemophilia and Thrombosis Centre, "Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico", Milan, Italy.
出版信息
Blood Transfus. 2018 Feb;16(2):215-220. doi: 10.2450/2017.0352-16. Epub 2017 May 15.
Abstract
摘要
相似文献
1
High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis.
Blood Transfus. 2018 Feb;16(2):215-220. doi: 10.2450/2017.0352-16. Epub 2017 May 15.
2
The economics of inpatient on-demand treatment for haemophilia with high-responding inhibitors: a US retrospective data analysis.
Haemophilia. 2012 Mar;18(2):284-90. doi: 10.1111/j.1365-2516.2011.02623.x. Epub 2011 Aug 4.
3
Hemostatic treatment using factor VIII concentrates for neutralizing high-responding inhibitors prior to CVAD insertion for immune-tolerance induction therapy.
Clin Appl Thromb Hemost. 2012 Jan-Feb;18(1):66-71. doi: 10.1177/1076029611412364. Epub 2011 Jul 6.
4
Successful immune tolerance induction with factor VIII/von Willebrand factor concentrate in an elderly patient with severe haemophilia A and a high responder inhibitor.
Blood Transfus. 2010 Jan;8(1):66-8. doi: 10.2450/2009.0078-09.
5
High titre inhibitor to factor VIII in a haemophilia carrier.
Haemophilia. 2014 May;20(3):e237-40. doi: 10.1111/hae.12417.
6
Inhibitors in Severe Hemophilia A: 25-Year Experience in Slovakia.
Semin Thromb Hemost. 2016 Jul;42(5):550-62. doi: 10.1055/s-0036-1581107. Epub 2016 May 28.
7
Long-term treatment course of a patient with mild haemophilia A who developed a high titre factor VIII inhibitor.
Haemophilia. 2014 Nov;20(6):e402-4. doi: 10.1111/hae.12491.
8
Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States.
J Med Econ. 2018 Aug;21(8):762-769. doi: 10.1080/13696998.2018.1468335. Epub 2018 Jun 6.
9
Factor VIII products in haemophilia A: one size fits all?
Thromb Haemost. 2015 May;113(5):911-4. doi: 10.1160/TH15-04-0273. Epub 2015 Apr 9.
10
Reduced early prophylaxis of children with haemophilia in a developing country, Turkey.
Haemophilia. 2011 Sep;17(5):e840-1. doi: 10.1111/j.1365-2516.2011.02581.x. Epub 2011 Jun 20.
引用本文的文献
1
"The times they are a-changin", ... or maybe not?
Blood Transfus. 2019 Nov;17(6):401-402. doi: 10.2450/2019.0259-19. Epub 2019 Dec 11.
2
Emicizumab for the treatment of haemophilia A: a narrative review.
Blood Transfus. 2019 May;17(3):223-228. doi: 10.2450/2019.0026-19.
3
Factors affecting the quality, safety and marketing approval of clotting factor concentrates for haemophilia.
Blood Transfus. 2018 Nov;16(6):525-534. doi: 10.2450/2018.0150-18. Epub 2018 Sep 3.
4
Further comments on "High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis".
Blood Transfus. 2019 Jan;17(1):86. doi: 10.2450/2017.0253-17. Epub 2017 Dec 22.
5
Reply to "High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis" by Messori et al.
Blood Transfus. 2019 Jan;17(1):85. doi: 10.2450/2017.0160-17. Epub 2017 Oct 3.
本文引用的文献
1
Economic analysis of not running tenders for recombinant Factor VIII procurement: a simplified analysis to estimate an otherwise unknown pharmacoeconomic index.
Eur J Hosp Pharm. 2016 Jul;23(4):219-223. doi: 10.1136/ejhpharm-2015-000728. Epub 2015 Dec 23.
2
A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A.
N Engl J Med. 2016 May 26;374(21):2054-64. doi: 10.1056/NEJMoa1516437.
3
Risk of inhibitors in previously untreated patients with hemophilia: a meta-analysis of literature studies.
Blood. 2015 Jun 11;125(24):3819-21. doi: 10.1182/blood-2015-01-621383.
4
Using value-of-information methods when the disease is rare and the treatment is expensive--the example of hemophilia A.
J Gen Intern Med. 2014 Aug;29 Suppl 3(Suppl 3):S767-73. doi: 10.1007/s11606-014-2880-3.
5
Purchasing factor concentrates in the 21st century through competitive tendering.
Haemophilia. 2013 Sep;19(5):660-7. doi: 10.1111/hae.12169. Epub 2013 May 28.
6
Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force.
Value Health. 2013 Mar-Apr;16(2):231-50. doi: 10.1016/j.jval.2013.02.002.
7
How we choose factor VIII to treat hemophilia.
Blood. 2012 May 3;119(18):4108-14. doi: 10.1182/blood-2012-01-394411. Epub 2012 Mar 12.
8
Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group.
Blood. 2003 Oct 1;102(7):2358-63. doi: 10.1182/blood-2003-03-0941. Epub 2003 Jun 19.
9
Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper.
Blood. 2000 Sep 1;96(5):1698-702.
Zotero 插件